logo-loader

Lannett gets FDA approval for generic version of neomycin sulphate tablets

Last updated: 09:05 13 Jun 2016 EDT, First published: 04:05 13 Jun 2016 EDT

Generic drugs
The orally taken drugs are typically prescribed for pre-operative sterilisation of the bowel

Lannett Company, Inc. (NYSE:LCI) has received approval from the US Food and Drug Administration (FDA) of its Abbreviated New Drug Application for neomycin sulphate tablets.

The 500 milligram (mg) tablets are the therapeutic equivalent to the reference listed drug, neomycin sulphate tablets USP, of Teva Pharmaceuticals USA, Inc (NYSE:TEVA). 

The orally taken drugs are typically prescribed for pre-operative sterilisation of the bowel and may be useful in the treatment of impending hepatic coma, including portal systemic encephalopathy.

Arthur Bedrosian, chief executive of generic drugs maker Lannett, said the approval expanded the company’s portfolio of anti-infective and antibiotic products. It represents the fifth approval gained by the company in 2016.

"We expect to commence marketing the product in the next several months, adding to our positive momentum as we enter the coming fiscal year," Bedrosian said.

 

Coniagas Battery Metals secures new key ground with focus on...

Coniagas Battery Metals (TSX-V:COS) CEO Frank Basa joined Steve Darling from Proactive to announce the company's strategic acquisition of key ground near SOQUEM’s Cardinal Property, located 80 km southeast of Chibougamau, Quebec. This acquisition underscores Coniagas’ commitment to capitalizing...

53 minutes ago